Perspectives · Service quality

The Quality Discount

Why quality doesn’t price a healthcare asset — it finds the deal, and times the turnaround

Corryk · July 2026

Service quality is easy to care about and hard to place in a valuation. It matters to everyone in a healthcare deal, yet it resists the model: it tends to arrive as a folder of inspection reports and a line in the risk register rather than as a number in the bridge. That is less an oversight than a genuine puzzle — in a sector where prices are largely set by payors, it is not obvious how quality should reach value at all. The instinct is that good quality must command a premium and poor quality a discount, that quality and value move together.

In a healthcare deal, quality is rarely the thing you pay for. Far more often, it is what you buy underperforming, and fix.

They do not, at least not in the way the instinct expects. In most of healthcare the price of the service is set by someone other than the buyer or the patient — a public tariff, an insurer’s fee schedule, a capitation rate — so being excellent earns no premium on the unit of revenue, and being mediocre suffers no discount on it — right up until quality fails badly enough to cost the licence, at which point the revenue goes with it. Across the ordinary range, quality is decoupled from the top line by design; only at the failing tail does it bite. Yet quality is unmistakably value-creative. The reconciliation of those two facts is the subject here, and it is more useful than either fact on its own.

The resolution is that quality does not price the service; it prices the business — and it does so as a rate of change, not a level. It protects volume at the bottom of the distribution (a poor rating costs occupancy, referrals and, in the limit, the licence). It supplies the classic operational play: buy an underperforming asset at a distress discount and remove the discount by fixing it. And it prices into the exit multiple and the cost of capital, where sustainability and tail risk are what the next buyer is really paying for. None of those channels runs through the tariff.

So the questions worth asking are not “is this asset good?” but “is it underperforming in a way I can fix, who else can see that, and will fixing it show up in the rating before I sell?” The evidence for that view is drawn chiefly from the one health system that rates every provider on a single scale and lets us watch what happens when they change hands — and the limit that matters most is a plain one: a better rating is not the same thing as better care.

A note on method. The evidence here is public. Its empirical spine is a transparent analysis of the United Kingdom’s Care Quality Commission (CQC) open data — chosen because the UK regulator publishes a comparable rating for every registered provider and preserves the record when ownership changes, which makes the quality–ownership relationship directly observable. The relationships we draw from it are general to consolidating healthcare, and we corroborate them with the peer-reviewed literature on ownership and care quality. Every exhibit cites its source; the inputs are public and the method is available on request.

— Corryk

In brief

Three principles frame the argument.

One — quality prices the business, not the service. Because healthcare prices are largely set by payors, quality earns no premium on the unit of revenue; the cross-sectional link between a provider’s rating and its revenue is close to noise. Quality is value-creative all the same, but as a rate of change, not a level, through three channels that bypass the tariff entirely: a volume-and-licence floor (poor ratings destroy occupancy and, at the tail, the right to operate), a turnaround delta (buy the distress discount, then remove it), and the exit multiple and cost of capital (sustainable, low-tail-risk cash flows re-rate). Quality lives in the multiple and the risk, never in the fee (Exhibit 1).

Two — ownership change is distress-driven, so quality is where you find and time the deal. In the UK — the one system that rates every provider on a single scale and preserves the record through a change of hands — sites that change operator carry a 22.9% “Requires improvement / Inadequate” rate going in, against 13.0% of the whole regulated population: 1.8×, rising to 3.4× for GP practices and 2.6× for acute hospitals (Exhibit 4–5). These deals are detectable because a change of operator forces a re-registration — roughly 11,500 of them in the current data — and most never surface in share-register or ultimate-beneficial-owner filings (Exhibit 6). After the change, among sites that are actually re-inspected, ratings improve rather than decline by about 1.5:1 (Exhibit 7). Distress in, improvement out: the shape of an operational turnaround.

Three — a better rating is not better care. The regulator’s rating is a measure of the tradeable quality of the business; it is not the same as the clinical outcome delivered to the patient, and the two can move in opposite directions. The peer-reviewed literature on cost-focused ownership is sobering: private-equity ownership of US nursing homes has been associated with roughly 10% higher short-term mortality (Gupta et al., Review of Financial Studies, 2024), and PE hospital acquisitions with a 25% rise in hospital-acquired conditions (Kannan et al., JAMA, 2023), even as the tradeable metrics hold (Exhibit 8–9). So the post-deal direction of real quality is not a law — it is a signal of the acquirer’s model. Which resolves into the only diligence question that matters: is the poor quality operational (fixable, a turnaround) or structural (a value trap wearing a discount)?

In healthcare M&A, quality is not a virtue you pay for — it is an origination, diligence and value-creation signal you act on: you buy it underperforming, you fix what is operational, you let the rating re-rate the multiple, and you never mistake the rating for the care.

A note on the data

Four things to hold in mind, because they are where quality signals are easiest to misread.

1 · A rating is not an outcome. Regulatory ratings measure the observable, governable quality of a business — safety systems, staffing, leadership, compliance. They are a decent proxy for tail risk and licence security, and a poor proxy for clinical results. We keep the two ideas separate throughout.

2 · Absence of a flag is not quality. No enforcement record means no action has been published, not that care is good; no accreditation means not-accredited, not sub-standard. We never read silence as a positive.

3 · Grades are not comparable across systems. A four-point inspection rating, a binary accreditation and a sanction list are different instruments on different scales. We anchor the empirical work in one internally-consistent system (the UK’s) rather than pretending a Danish, French and British rating share an axis.

4 · Correlation around a deal is not proof the deal caused it. Post-acquisition rating changes can reflect mean reversion, re-inspection timing or the new owner’s reporting as much as genuine operational uplift. We flag the mechanism wherever we lean on it, and we prefer the honest, smaller number to the flattering one.

Quality prices the business, not the service

1 · The revenue paradox: flat across the range, a cliff at the bottom

Start with the fact that unsettles the intuition. In most of healthcare, the provider does not set its own price. A care home is paid a fee per resident negotiated with a local authority or an insurer; a clinic is paid a tariff per procedure; a GP practice is paid largely by capitation. Within a given payor and geography, a five-star operator and a two-star operator are paid nearly the same for the same unit of care. Excellence buys no premium on that unit; mediocrity suffers no discount on it. Price is decoupled from quality by the architecture of the system.

It follows — and it is worth stating carefully, because the instinct runs the other way — that across the ordinary range of quality, a provider’s rating barely tracks its revenue. The price is fixed by the payor, so excellence earns no premium on it; and where demand for beds or appointments outruns supply, a “Good” site and an “Outstanding” site both run near-full, so excellence earns little extra volume either. Strip out size (larger operators score a little better because scale buys management and slack) and the residual link between quality and revenue, across the healthy middle of the distribution, is close to zero. Underwrite a thesis in which a better rating earns a higher top line and you are, in most publicly-funded subsectors, underwriting a mirage.

But “close to zero across the range” is not “zero everywhere,” and this is the distinction that trips people up. Quality’s effect on revenue is not a smooth slope; it is flat, then a cliff. Take two identical 60-bed homes in the same council area, one “Good” and one “Outstanding”: the council sets the same fee, both run near-full, and revenue is all but identical — flat. Now push one to “Inadequate” with an admission embargo: it can no longer take new residents, occupancy bleeds away over months, and revenue collapses — the cliff. A straight line fitted across a population of mostly-sound providers reads as no relationship at all, even though the cliff is devastating, because the cliff is rare and sits entirely in the tail. So the honest formulation is not that quality is irrelevant to revenue — at the bottom it plainly is not — but that quality does not earn a revenue premium; it insures against a revenue collapse. That asymmetric, tail-shaped relationship is Channel one of the next section, and it is the reason quality belongs in the risk and the multiple rather than the revenue forecast: a floor is worth a lower discount rate, not a higher sales line.

And yet every experienced operator will tell you quality creates value, and they are right. The paradox dissolves once you notice that the two statements are about different objects. Revenue is a level. Value creation is a change. Quality is essentially uncorrelated with the level and meaningfully correlated with the change. You can hold both ideas at once because they are not in contact.

2 · A derivative, not a level: the three channels

If quality does not move revenue, how does it move value? Through three channels, none of which touches the tariff (Exhibit 1).

Channel one: the volume-and-licence floor. Quality is asymmetric. It is worthless as an upside pricing lever and decisive as a downside volume guard. A poor inspection does not cut your fee; it cuts your throughput — regulators impose admission embargoes, commissioners divert referrals, families move relatives elsewhere — and at the tail it removes the licence altogether. The economic content of quality lives at the bottom of the distribution, in catastrophe avoided, not at the top in premium earned. That is precisely why a straight-line correlation with revenue reads as nothing: the relationship is a floor, not a slope.

Channel two: the turnaround delta. This is where the money is. Poorly-rated assets change hands at a discount, because the seller is often distressed and the buyer is pricing embedded remediation and regulatory risk (the distress skew is real and large). The operational buyer purchases that discount, fixes the operation — management, staffing, systems, capital — lifts the rating, restores occupancy and referrals, and captures the spread between the distressed entry price and the stabilised value. Quality improvement is the mechanism and the evidence of the turnaround; the return is the spread, not a fee that never moved.

Channel three: the exit multiple and the cost of capital. Two platforms with identical EBITDA do not clear at the same multiple if one is studded with “Requires improvement” sites and the other is not, because the next buyer, the lender and the ratings desk price quality as sustainability of cash flow and absence of regulatory tail risk. Quality shows up in the multiple and the financing cost, not the operating line. It is, in the most literal sense, priced into the business rather than the service.

Exhibit 2 · Quality’s three jobs in a deal — none of them is “set the price”

What quality actually does across the deal lifecycle.

Corryk Research framework.

The corollary is a discipline, not a slogan. Do not pay up for a grade. A pristine rating is already in the price and earns you nothing on the tariff; it buys a lower-risk, lower-return asset. This is not an argument to ignore quality — the downside floor is real, and a genuinely unfixable asset is worth avoiding at any price — it is an argument not to capitalise a revenue premium that does not exist. The excess return is in the assets whose quality is recoverable and whose recovery you can execute — which is why the rest is about finding them, and about the one thing that decides whether the trade works: whether the poor quality is the kind you can fix.

3 · How to read a rating

Before the evidence, a word on the instrument, because “quality data” is not one thing and the four kinds are not interchangeable. Reading them as if they were interchangeable is an easy way to reach the wrong conclusion.

Exhibit 3 · Four instruments, four meanings

What each kind of quality signal actually tells a buyer — and how to weight it.

Corryk Research framework. Instruments illustrative of the regimes operating across European health systems.

Two rules fall out of the table and run through everything that follows. First, only a graded, dated, repeated signal supports a trajectory — the change-over-time where quality’s value lives. An accreditation tells you an asset cleared a bar once; a sanction tells you something went wrong once; only a repeated inspection rating tells you which way an asset is moving, which is the origination signal that matters. Second, the absence of a black mark is not a clean bill of health. A site with no published enforcement is a site no one has published enforcement about — a fact about the record, not the care. Silence is easily mistaken for a clean bill of health; it is neither — only the absence of a record.

The distress-and-turnaround cycle

The evidence in this Part is drawn from the UK Care Quality Commission’s published open data. The UK is the natural laboratory because CQC inspects every registered provider and rates most sectors on one four-point scale (Outstanding / Good / Requires improvement / Inadequate) — dentistry is inspected but not routinely rated — and preserves the location record when ownership changes — so a change of operator, and the quality on either side of it, can be observed directly. The behaviour we read off it — buyers acquiring underperforming assets and improving them — is a general feature of healthcare consolidation, not a British peculiarity. The magnitudes are British; the mechanism — payors set the price, distressed assets trade at a discount, and a regulator can switch off volume — is structural, and it travels.

4 · Ownership change is distress-driven

If quality were priced into revenue, you would expect assets to trade at random with respect to their rating. They do not. Sites that change operator are drawn disproportionately from the bottom of the rating scale. Across the current CQC population, 13.0% of rated locations sit in the two distressed tiers — “Requires improvement” or “Inadequate.” Among sites that changed operator, the rate going into the change is 22.9% (Exhibit 4). Traded assets are 1.8× more likely to be distressed than the population, and roughly half as likely to be “Outstanding.”

The skew is not uniform, and the variation is itself informative (Exhibit 5). It is sharpest where quality is most visibly a franchise on a public contract and least tolerant of failure: GP practices trade distressed at 3.4× the population rate (16.8% of traded practices vs 4.9% of all practices), and acute hospitals at 2.6×. It is real but milder in care homes (1.45×) — the largest rated deal category by volume — and essentially absent in domiciliary care (1.06×), where ratings are compressed and ownership turns over for reasons less tied to quality. The pattern says something a buyer can use: in primary care and hospitals, a distressed rating is a strong marker of a motivated seller; in home care, it is barely a marker at all.

Read through the lens of Part I, this is exactly what the turnaround channel predicts. The assets that come to market are disproportionately the ones carrying an embedded discount — regulatory risk, remediation cost, a motivated or forced seller. The distress skew is the deal funnel made visible. It is not evidence that acquirers cause poor quality; it is evidence that poor quality causes deals.

5 · The re-registration signal

There is a second, quieter finding buried in how these deals were detected, and it is arguably the more useful one for origination. Many changes of ownership in healthcare leave no trace in the places dealmakers look. A great deal of consolidation happens at the asset level — a clinic, a home, a practice is transferred — without a share sale, a change in ultimate beneficial ownership, or a filing that a deal database would capture. These transactions are, to the standard toolkit, invisible.

But in a regulated sector they are not invisible to the regulator. When an operator changes, the site is de-registered under the old provider and re-registered under the new one — same address, same building, new licence-holder. That re-registration is a public event. Matching de-registered locations to newly-registered ones at the same address under a different provider therefore recovers the ownership change directly from the regulatory record. Applied to the CQC data, the method surfaces roughly 11,500 cross-operator changes in the current window (Exhibit 6) — a deal-flow map assembled from a source that has nothing to do with corporate filings.

A word on what that number is and is not. It counts changes of operator at a site, net of the obvious intra-group reshuffles that share a provider name — which makes it deliberately broader than “announced M&A.” It includes arm’s-length acquisitions, but also lease and management transfers, distress hand-backs, and corporate reorganisations that a deal database would never log. For origination that breadth is the point — every one is a site where operational control changed hands and an incumbent relationship ended — but it should be read as a map of control changing hands, not as a count of eleven thousand sale processes.

The category mix is revealing. Dentistry and care homes dominate the churn — the two most fragmented, most owner-operated corners of the sector, exactly where single-site transfers happen constantly and share-deal databases are thinnest. GP practices, hospitals and diagnostics follow. For an acquirer, the signal cuts two ways: it is an origination feed (a live register of who is changing hands, ahead of any announced process), and it is a competitive-intelligence feed (a near-real-time map of rivals’ buy-and-build activity). Neither is available from conventional deal data, because conventional deal data is looking at the wrong layer.

6 · The turnaround signature

Distress in is only half a thesis. The other half is whether quality actually improves once the asset changes hands — whether the turnaround channel shows up in the record. It does, modestly (Exhibit 7). Among sites that changed operator and were subsequently re-inspected under the new owner, 22% improved their rating and 15% declined, with the balance unchanged — improvement beating decline by about 1.5 to 1. On the wider set that includes ratings mechanically carried over at re-registration, the tilt is gentler still (15% up, 11% down), because carried-over ratings cannot move.

Two things must be said about this exhibit, because it is easy to over-read in either direction. It is real: the direction is up, consistent with a sector in which the marginal buyer of a distressed asset is an operational consolidator with a remediation playbook, and it is what you would expect if the distress discount is genuinely being worked off. But it is modest: most sites do not move, a rating change is a slow and lagging measure, and a lift from “Requires improvement” to “Good” is a governance-and-compliance achievement, not proof that patients are better off. The turnaround is a business event that the rating captures well. Whether it is a care event is another matter — and the answer is not the comfortable one.

There is also a statistical humility worth keeping. An asset bought at its rating trough tends to drift back up whoever owns it — regression to the mean, reinforced by the fact that an inspection bad enough to force a sale is usually followed by a re-inspection once the glaring failings are addressed. Some of that 22% is mean reversion, not managerial heroics. This does not weaken the trade — buying at the trough and capturing the recovery is the trade — but it should keep a buyer honest about how much of a “turnaround” is its own work and how much is gravity.

7 · Dispersion within the group: the integration tell

So far we have treated quality as a property of a single site. For a platform buyer, the more revealing object is the distribution of quality across an operator’s sites. A group is rarely uniformly good or bad; it is Outstanding here, Requires-improvement there. The spread of ratings within a group — its dispersion — is one of the most informative diligence signals available, and one a headline average hides.

Dispersion reads in two directions. On the buy-side of a serial acquirer, wide dispersion is a warning: it says the group has been buying assets of uneven quality and has not yet imposed a common operating standard — integration risk made measurable, and a caution against paying a premium multiple for a “platform” that is really a holding company of un-integrated sites. On the target side, dispersion is an opportunity map: the weak sites in an otherwise sound group are the addressable turnaround within the deal, and the gap between the group’s best and worst sites is a rough ceiling on the operational upside a competent owner can capture. Two groups with the same average rating and different dispersions are not the same asset; the tighter one is a better business and the looser one is a better project.

The average rating of a multi-site group can hide as much as it shows. It is worth pulling the rating of every site, look at the spread and — where the regulator dates its ratings — the direction of travel. A rising average with narrowing dispersion is a well-run integrator. A flat average with widening dispersion is a roll-up outrunning its operating model. The average alone hides both.

8 · A better rating is not better care

Now the caveat that governs everything above, and that separates honest analysis from a sales pitch. Everything above is measured in the currency of the regulator’s rating. That rating is a good measure of the tradeable quality of a business — its safety systems, its governance, its licence security, the things that protect volume and re-rate a multiple. It is a much weaker measure of the clinical outcome delivered to the patient. And under cost-focused ownership, the two can move in opposite directions (Exhibit 8).

The evidence for the divergence is not anecdotal; it is some of the most-cited work in health economics of the last few years (Exhibit 9). In the largest study of its kind, private-equity ownership of US nursing homes was associated with roughly a 10% increase in short-term mortality among Medicare residents, alongside falls in nurse staffing and compliance and a 19% rise in cost billed to the taxpayer (Gupta, Howell, Yannelis & Gupta, Review of Financial Studies, 2024). In hospitals, private-equity acquisition was associated with a 25% increase in hospital-acquired conditions — falls and infections — despite the acquired hospitals treating lower-acuity patients (Kannan, Bruch & Song, JAMA, 2023). In the English care-home sector, for-profit and private-equity-backed chains have tended to rate worse on quality than not-for-profit and public provision (Age and Ageing, 2022).

Exhibit 10 · The evidence base on ownership and quality

Peer-reviewed studies relating ownership change to measured quality and cost.

Sources as cited. Clinical/financial outcomes; distinct from the regulatory rating in Exhibit 4–7.

How does this square with the turnaround signature, where ratings went up? It squares because they measure different things. A cost-focused owner can lift a home’s rating — tightening documentation, governance and the specific items an inspector scores — while simultaneously thinning the staffing that drives the outcomes those studies measure. The rating is manageable; the mortality curve is not managed the same way. For the dealmaker this is not a reason to distrust the rating — the rating is exactly the right instrument for the business questions of volume, licence and multiple — but it is a hard reason never to present a rating improvement as proof of better care. The rating tells you the asset got more valuable. It does not tell you the patient got better. Holding that distinction is the difference between a defensible thesis and a reputational one.

It also converts the post-deal trajectory into a genuinely useful signal of the acquirer’s model. An owner whose ratings and staffing both rise is running an operational-improvement play; an owner whose ratings hold while staffing and outcomes erode is running a cost-extraction play. Watching which one a competitor is executing — site by site, over time — is as close as this data gets to reading a rival’s strategy off the public record.

So Exhibit 8 depicts one of two cases, not a law. An operational-improvement owner moves both lines up together; a cost-extraction owner is where they part. The point is not that acquisition harms care — it is that the rating and the outcome are distinct measurements, and which way the second one moves is a fact about the buyer, not about the deal.

Where the relationship pays

9 · Subsector patterns

The quality-as-deal-signal is not equally useful everywhere. It is sharpest where three conditions coincide: providers are graded on a comparable scale, revenue is exposed to a payor who can withdraw it, and ownership is fragmented enough that distressed assets actually come to market. Where those hold, quality originates and times deals; where they do not, quality recedes and other signals lead.

Exhibit 11 · Where the quality signal earns its keep, by subsector

How the distress-and-turnaround relationship applies across the main care subsectors.

Corryk Research synthesis; signal strengths from the CQC analysis in Exhibit 4–7 and the regime characteristics of each subsector.

The through-line: the rating is a care-home, primary-care and hospital instrument. In the practice-based subsectors (dental, and much of optical and physiotherapy), the useful signal is not the grade but the transfer — the constant re-registration churn that marks a fragmenting, consolidating market. A buyer who wants a quality-led origination edge should point it at the graded, payor-exposed subsectors; a buyer in the practice subsectors should point it at the churn feed instead.

10 · The buyer landscape

Who is on the other side of these deals, and how does quality figure in their models? Three broad types, and the quality signal means something different to each (Exhibit 12).

Exhibit 12 · Buyer types and the role quality plays

How quality figures in each acquirer’s model. Named operators are illustrative and drawn from public record.

Corryk Research synthesis. Public examples of large healthcare consolidators include care operators such as HC-One and Care UK (UK) and emeis (ex-Orpea), Clariane (ex-Korian) and DomusVi (Continental Europe); lab platforms Synlab, Unilabs and Cerba; hospital groups Ramsay Santé and Mediclinic; and integrated regional groups such as Penta (Dr.Max, Svet zdravia) and AGEL in Central Europe. Cited illustratively, not as transactions.

The practical point for an acquirer is to know which game the other side is playing, because it prices differently. Against operational consolidators you are competing for the same distressed assets on the same turnaround logic, and the edge is execution and origination speed — which is where the re-registration feed pays. Against financial buyers you may be able to pay more for the right assets because you underwrite the operational recovery they discount; but you should also expect the assets they have already owned to carry the rating-vs-outcome gap, and diligence accordingly. The quality signal is not just a lens on the target — it is a lens on the competition.

11 · Fixable, or a value trap?

Everything reduces, in the end, to a single diligence question. The distress skew guarantees that the assets on offer are disproportionately poorly-rated. The turnaround signature says that poor quality is, on average, recoverable. But “on average” hides the whole risk, because poor quality comes in two kinds and only one of them is a bargain (Exhibit 12…13).

Operational poor quality is fixable. Weak management, thin or badly-rostered staffing, broken systems, poor documentation, a lapsed governance routine — these are the raw material of a turnaround, because a competent owner with capital and a playbook can change them, and the rating (and the volume, and the multiple) will follow. Structural poor quality is not. A home in the wrong location for its case-mix, a building that cannot meet modern standards without uneconomic capex, a catchment that cannot support the service, a payor relationship that is structurally loss-making — these look identical to operational distress on the inspection report and at the entry price, but they do not respond to the playbook. They are cheap for a reason, and the discount is not a discount; it is the price.

The entire edge in distressed healthcare acquisition is the ability to tell the two apart before completion — to look past the rating (which does not distinguish them) at the cause. That is what separates the turnaround in the upper-left of the exhibit from the value trap in the lower-left. It is also why quality is a diligence signal and not a screening rule: the rating gets you to the shortlist of distressed assets, but only a causal read of why each one is distressed tells you which are worth owning. Without that causal read, the value traps do not disappear — they surface after completion instead.

Implications

12 · The dealmaker’s playbook

Pulling this together into what an acquirer actually does with it (Exhibit 14). The organising idea is unchanged: quality is not a price you pay, it is a signal you act on — to find the deal, to size the risk, and to time the turnaround.

Exhibit 14 · Using quality across the deal lifecycle

The practical playbook implied by Parts I–III.

Corryk Research framework.

13 · Catalysts

The relationship described here is not fixed. Four forces would change it, and each is worth watching.

Outcome-based reimbursement. The single biggest structural change would be payors tying money to results. To the extent value-based-care and pay-for-outcome models spread, quality would begin to reach the revenue level directly — the one channel it does not use today — and the “quality doesn’t price the service” premise would weaken at the margin. This is slow and uneven, but it is the thing that would most alter the thesis.

Scrutiny of cost-focused ownership. The outcome literature has become a policy input on both sides of the Atlantic, and regulators and competition authorities are increasingly attentive to private-equity roll-ups in care. That raises the tail risk of the leverage-and-cost-out model precisely where the rating-vs-outcome gap is widest — and makes the operational-improvement play, which closes that gap rather than exploiting it, the more durable one.

Rating-regime change. The instruments themselves evolve — inspection frameworks are periodically overhauled, which changes what a rating captures and can reset comparability across a transition. A buyer relying on the trajectory signal has to know when the ruler changed.

Consolidation itself. Every turnaround executed removes a distressed asset from the funnel. As the fragmented subsectors consolidate, the supply of cheap, fixable, poorly-rated assets thins — the distress discount is, in part, a function of how far consolidation has already run. The play is most available early in a subsector’s consolidation and most competed late in it.

14 · The bottom line

Quality is the most moralised and least understood variable in a healthcare deal. It is moralised because it is about care, and it should be. It is misunderstood because that moral weight gets mistaken for financial logic — the assumption that good must be worth more and bad must be worth less, in a sector where the payor has already decided what each is worth. The financial logic runs the other way. You do not make money owning the good asset; you make it fixing the bad one, and you realise it not on the fee, which never moves, but on the volume you protect, the discount you remove, and the multiple you re-rate.

So the useful questions are narrow and unsentimental. Not “is this asset good?” but “is it underperforming in a way I can fix, is the cause operational or structural, who else can see it changing hands, and will the fix show up in the rating before I sell?” Answer those and quality becomes what it should have been all along in the model: not a virtue to be admired in a diligence folder, but a signal to be acted on. And keep, always, the one honest line that the numbers insist on — a better rating means a more valuable business, and it does not, by itself, mean a better-cared-for patient. Held together, those two truths are what make quality genuinely useful in a deal — a signal to act on, not a virtue to price.

— Corryk

Comments, corrections or questions on this article: perspectives@corryk.com.